163 related articles for article (PubMed ID: 36879149)
21. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
[TBL] [Abstract][Full Text] [Related]
22. Germline CEBPA mutation in familial acute myeloid leukemia.
Boada M; Catalán AI; Ottati C; Bentancour F; Lens D; Guillermo C; Grille S
Hematol Rep; 2021 Sep; 13(3):9114. PubMed ID: 34733449
[TBL] [Abstract][Full Text] [Related]
23. Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis.
Li HY; Deng DH; Huang Y; Ye FH; Huang LL; Xiao Q; Zhang B; Ye BB; Lai YR; Mo ZN; Liu ZF
Eur J Haematol; 2015 May; 94(5):439-48. PubMed ID: 25227715
[TBL] [Abstract][Full Text] [Related]
24. GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations.
Green CL; Tawana K; Hills RK; Bödör C; Fitzgibbon J; Inglott S; Ancliff P; Burnett AK; Linch DC; Gale RE
Br J Haematol; 2013 Jun; 161(5):701-705. PubMed ID: 23560626
[TBL] [Abstract][Full Text] [Related]
25. Complexity of CEBPA dysregulation in human acute myeloid leukemia.
Pabst T; Mueller BU
Clin Cancer Res; 2009 Sep; 15(17):5303-7. PubMed ID: 19706798
[TBL] [Abstract][Full Text] [Related]
26. Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).
Brown AL; Hahn CN; Scott HS
Blood; 2020 Jul; 136(1):24-35. PubMed ID: 32430494
[TBL] [Abstract][Full Text] [Related]
27. CCAAT/enhancer binding protein-alpha polymorphisms occur more frequently than mutations in acute myeloid leukemia and exist across all cytogenetic risk groups and leukemia subtypes.
Leecharendkeat A; Tocharoentanaphol C; Auewarakul CU
Int J Cancer; 2008 Nov; 123(10):2321-6. PubMed ID: 18729193
[TBL] [Abstract][Full Text] [Related]
28. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
29. Acquired somatic variants confirm the independent development of AML in monozygotic twins with germline CEBPA variant.
Podgornik H; Šućurović S; Škerget M; Debeljak M; Zver S
Leuk Res; 2022 Oct; 121():106933. PubMed ID: 36031690
[No Abstract] [Full Text] [Related]
30. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.
Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Zimmermann M; Peeters JK; Valk PJ; Balgobind BV; Sonneveld E; Kaspers GJ; de Bont ES; Trka J; Baruchel A; Creutzig U; Pieters R; Reinhardt D; Zwaan CM
Haematologica; 2011 Mar; 96(3):384-92. PubMed ID: 21134981
[TBL] [Abstract][Full Text] [Related]
31. First report of multiple CEBPA mutations contributing to donor origin of leukemia relapse after allogeneic hematopoietic stem cell transplantation.
Xiao H; Shi J; Luo Y; Tan Y; He J; Xie W; Zhang L; Wang Y; Liu L; Wu K; Yu X; Cai Z; Lin M; Ye X; Huang H
Blood; 2011 May; 117(19):5257-60. PubMed ID: 21403128
[TBL] [Abstract][Full Text] [Related]
32. CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk.
Park SH; Chi HS; Cho YU; Jang S; Park CJ
Leuk Res; 2013 Nov; 37(11):1488-94. PubMed ID: 24054719
[TBL] [Abstract][Full Text] [Related]
33. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K
J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735
[TBL] [Abstract][Full Text] [Related]
34. Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Matsuo H; Kajihara M; Tomizawa D; Watanabe T; Saito AM; Fujimoto J; Horibe K; Kodama K; Tokumasu M; Itoh H; Nakayama H; Kinoshita A; Taga T; Tawa A; Taki T; Tanaka S; Adachi S
Blood Cancer J; 2014 Jul; 4(7):e226. PubMed ID: 25014773
[TBL] [Abstract][Full Text] [Related]
35. Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia.
Ahn SY; Kim T; Kim M; Song GY; Jung SH; Yang DH; Lee JJ; Kim MY; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim HJ; Ahn JS; Kim DDH
Cancer Res Treat; 2023 Jul; 55(3):1011-1022. PubMed ID: 36701843
[TBL] [Abstract][Full Text] [Related]
36. Detection of CEBPA double mutants in acute myeloid leukemia using a custom gene expression array.
van Vliet MH; Burgmer P; de Quartel L; Brand JP; de Best LC; Viëtor H; Löwenberg B; Valk PJ; van Beers EH
Genet Test Mol Biomarkers; 2013 May; 17(5):395-400. PubMed ID: 23485358
[TBL] [Abstract][Full Text] [Related]
37. Mutations of the GATA2 and CEBPA genes in paediatric acute myeloid leukaemia.
Shiba N; Funato M; Ohki K; Park MJ; Mizushima Y; Adachi S; Kobayashi M; Kinoshita A; Sotomatsu M; Arakawa H; Tawa A; Horibe K; Tsukimoto I; Hayashi Y
Br J Haematol; 2014 Jan; 164(1):142-5. PubMed ID: 24033149
[No Abstract] [Full Text] [Related]
38. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis.
Pabst T; Eyholzer M; Fos J; Mueller BU
Br J Cancer; 2009 Apr; 100(8):1343-6. PubMed ID: 19277035
[TBL] [Abstract][Full Text] [Related]
39. The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression.
Kuo YY; Hou HA; Chen YK; Li LY; Chen PH; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Chou WC; Liu CY; Tang JL; Yao M; Tien HF
Haematologica; 2014 Dec; 99(12):1799-807. PubMed ID: 25193961
[TBL] [Abstract][Full Text] [Related]
40. [CEBPA gene mutation analysis in acute myeloid leukemia].
Han C; Lin D; Ai XF; Wang F; Sun HY; Wang M; Mi YC; Wang JX; Ru K
Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):566-71. PubMed ID: 23906447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
